COVID-19: Russia approves single-dose Sputnik Light vaccine for use
Representational Image
Moscow: Health officials in Russia have approved a single-dose version of the Sputnik V coronavirus vaccine, the developers of the shot said.
The Russian Direct Investment Fund (RDIF), which helped finance the vaccine, said in a statement that Sputnik Light had âdemonstrated 79.4 percent efficacy compared to 91.6 percent for the two-shot Sputnik V.
The results, it said, were drawn from âdata taken from 28 days after the injection was administered as part of Russiaâs mass vaccination program between 5 December 2020 and 15 April 2021 . The Russian vaccine has been approved for use in over 60 countries.
Russia Registers One-Dose Sputnik Light Coronavirus Jab May 6, 2021 Sputnik Light demonstrated 79.4% efficacy compared to 91.6% for the two-shot Sputnik V, its developers said. Valery Sharifulin / TASS
Health officials in Russia approved a single-dose version of the Sputnik V coronavirus vaccine, the developers of the shot said Thursday.
The Russian Direct Investment Fund (RDIF), which helped finance the vaccine, said in a statement that Sputnik Light demonstrated 79.4% efficacy compared to 91.6% for the two-shot Sputnik V. news
The Russian vaccine has been approved for use in over 60 countries.
But it has not yet been approved by the European Medicines Agency (EMA) or the United States Food and Drug Administration (FDA).
A coronavirus vaccine being prepared for use. Credit: Public DomainGreece started on Wednesday using the Johnson & Johnson (J&J) vaccine against the coronavirus to inoculate its citizens.The vaccine, which is the only one that protects people from coronavirus with only a single dose, has already been shipped to Greece. 33.6 thousand doses of the vaccine…
AI tech helps Taiwan doctors identify brain tumors more accurately
05/04/2021 10:48 PM
NTUH oncologist Hsu Feng-ming. CNA photo May 4, 2021
Taipei, May 4 (CNA) A technology that uses artificial intelligence has helped doctors at National Taiwan University Hospital (NTUH) identify tiny brain tumors which could easily have been missed by traditional manual contouring, the hospital said Tuesday.
At a press conference, NTUH Superintendent Wu Ming-shiang (吳明賢) described VBrain, a brain tumor auto-contouring system developed by Boston-based Vysioneer LLC, as an eagle eye.
The system has been used at NTUH for the past 18 months as part of clinical trials and helped doctors treat more than 100 patients with brain tumors, including a terminally ill woman whose lung cancer metastasized to her brain.
BRASÃLIA, BRAZIL Brazil s health regulator said Thursday its decision to reject the Russian-made Sputnik V coronavirus vaccine was based on the developer s own data, after the latter threatened to sue for defamation. Brazilian regulators decision Monday to deny emergency use authorization for the vaccine has blown up into an all-out international row, with Sputnik V s makers accusing them of knowingly spreading false and inaccurate information without testing the vaccine themselves. The Brazilian agency, Anvisa, based the decision on evidence the vaccine carried a live version of adenovirus, a common cold-causing virus. It fired back defensively in a press conference that it had drawn that conclusion from information submitted by the Sputnik V vaccine developer itself.